Schering-Plough Announces FDA Approval Of NOXAFIL(R) (Posaconazole) For Treatment Of Oropharyngeal Candidiasis (OPC)

... Schering-Plough Corporation (NYSE: SGP) today reported that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL(R) (posaconazole) Oral Suspension for the treatment of oropharyngeal candidiasis (OPC), including infections refractory to itraconazole and/or fluconazole. OPC is a fungal infection of the mouth and throat caused by the yeast Candida. [click link for full article] ...